🇺🇸 FDA
Pipeline program

Glatiramer Acetate, N-Acetylcysteine

GA 9015

Phase 2 small_molecule completed

Quick answer

Glatiramer Acetate, N-Acetylcysteine for Relapse Remitting Multiple Sclerosis is a Phase 2 program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Teva Pharma GmbH
Indication
Relapse Remitting Multiple Sclerosis
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials